State of the art of ICD programming: Lessons learned and future directions by M. H. Mastenbroek et al.
REVIEWARTICLE
State of the art of ICD programming: Lessons learned
and future directions
M. H. Mastenbroek & S. S. Pedersen & H. Versteeg &
P. A. Doevendans & M. Meine
# The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract The lifesaving benefits of implantable cardioverter
defibrillator (ICD) therapy are more and more weighted
against possible harm (e.g. unnecessary device therapy, pro-
cedural complications, device malfunction etc.) which might
have adverse effects on patients’ perceived health status and
quality of life. Hence, there has been an increasing interest in
the optimisation of ICD programming to prevent inappropri-
ate and appropriate but unnecessary device therapy. The pur-
pose of the current report is to give an overview of research
into the optimisation of ICD programming and present the
design of the on-going ENHANCED-ICD study. The
ENHANCED-ICD study is a prospective, safety monitoring
study enrolling 60 primary and secondary prophylactic ICD
patients at the University Medical Center Utrecht. Patients
implanted with any type of ICD with SmartShock
technologyTM, and between 18–80 years of age, were eligible
to participate. In all patients a prolonged detection of 60/80
intervals was programmed. The primary objective of the study
is to investigate whether enhanced programming to further
reduce ICD therapies is safe. The secondary objective is to
examine the impact of enhanced programming on (i)
antitachycardia pacing and shocks (both appropriate and in-
appropriate) and (ii) quality of life and distress. The first
results of the ENHANCED-ICD study are expected in 2015.
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Introduction
When implantable cardioverter defibrillator (ICD) treatment
was initially introduced, ICDs were exclusively implanted in
patients with documented sustained ventricular tachycardia
(VT) or ventricular fibrillation (VF) to prevent sudden cardiac
death (SCD, secondary prevention). Nowadays, the ICD is the
first-line treatment for a much broader population of patients,
including patients with an anticipated risk for arrhythmic
death (primary prevention) [1]. While in the past mortality
reduction was the primary goal of ICD therapy, in the last
decade this lifesaving benefit is more and more weighted
against possible harm in the form of unnecessary device
therapy, proarrhythmic potential, procedural complications,
infection, device malfunction, and manufacturer recalls,
which might have adverse effects on patients’ perceived
health status and quality of life [2, 3]. Hence, there has been
an increasing interest in the optimisation of ICD programming
to prevent inappropriate and unnecessary appropriate device
therapy (either antitachycardia pacing (ATP) or shock), as it is
associated with heart failure and prognosis, and may lower
patient-perceived health status. The purpose of the current
report is to give an overview of research into the optimisation
of ICD programming and present the design of the ENHAN
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CED device programming to reduce therapies and improve
quality of life in Implantable Cardioverter Defibrillator pa-
tients (ENHANCED-ICD) study, which started in April 2013.
Prolonged life at the expense of unnecessary ICD therapy
There is no doubt about the efficacy of ICD therapy in
prolonging the life of patients who are at risk for SCD [4–6].
Secondary prevention ICD trials (e.g. the Antiarrhythmics
Versus Implantable Defibrillators (AVID) trial, the Canadian
Implantable Defibrillator Study (CIDS), and the Cardiac Ar-
rest Study Hamburg (CASH)) have shown high numbers of
appropriate ATP and shocks in patients during follow-up
[7–9], whereas these numbers are lower in patients receiving
an ICD for primary prevention [5, 6, 10]. Remarkably, the
Multicenter Automated Defibrillator Implantation Trial II
(MADIT II) [6] and the Sudden Cardiac Death in Heart
Failure Trial (SCD-HeFT) [5], both primary prevention ICD
trials, showed that the number of appropriate ICD therapies
for VT/VF in the ICD group outnumbered sudden cardiac
arrest in the control group (either conventional medical ther-
apy with or without amiodarone) by a factor of 2 to 3 [11].
Thus, ICD therapy was probably delivered for non-life-
threatening ventricular tachyarrhythmias (haemodynamically
stable or non-sustained VTs).
Painfree therapy for fast VT
One of the first trials that aimed to reduce appropriate ICD
shocks was the Pacing Fast VT Reduces Shock Therapies
(PainFREE Rx II) trial, which started in 2001 and randomised
ICD patients to either ATP or shock as first therapy for fast VT
(FVT) [12]. It was the first prospective randomised trial to
demonstrate that ATP was safe and effective compared with
shocks for treating FVT. ATP terminated 73 % of FVT epi-
sodes (which made up 76 % of all ventricular arrhythmias
conventionally programmed to shock) with a very low risk of
acceleration and syncope and no difference in mortality. Sub-
sequently, the Avoid Delivering Therapies for Non-Sustained
Arrhythmias in ICD Patients III (ADVANCE III) trial showed
that in prolonged arrhythmia detection ATP efficacy (with an
ATP-during-charge feature) was still as high as 44 % [13].
Noise – SVT – VT discrimination
The most common triggers for inappropriate shocks are sup-
raventricular tachycardia (SVT), intracardiac oversensing,
lead fracture or other extracardiac noise [14, 15]. This knowl-
edge has led to the development of more sophisticated in-
device automated detection algorithms to increase ICD spec-
ificity without reducing sensitivity when treating patients at
risk for SCD. In the PainFREE Rx II trial, over 11±3 months,
inappropriate therapies due to misclassification of rapidly
conducted SVTs occurred in 15 % of primary and secondary
prevention patients and accounted for more than one-third of
all therapies and≈40 % of all shocks in both groups [16]. The
PainFREE SST study was designed to investigate the ability
of new algorithms (SmartShock™ Technology) to reduce in-
appropriate shocks by enrolling up to 2000 primary and
secondary prophylactic patients implanted with an ICD or
cardiac resynchronisation therapy defibrillator (CRT-D) de-
vice. First results showed that this new technology resulted in
a low incidence of inappropriate ICD shocks (1.6 and 2.3 % in
primary and secondary prevention patients, respectively),
while maintaining flexibility in detection rate [17].
Detection duration and unnecessary ICD therapy
The fact that 34 % of detected FVT episodes in the shock arm
of the PainFREE Rx II trial terminated during the 3.3 s
(median) of capacitor charging suggested that a longer delay
would further reduce unnecessary ATP [12]. It was intuitively
assumed that increased duration of tachycardia might increase
syncope. However, delaying detection to a number of intervals
to detect (NID) of 18 out of 24 beats (18/24) proved safe
because arrhythmic syncope (8 of 1837, 0.5 %) did not in-
crease compared with PainFREE Rx (13 of 1248, 2.0 %),
which used a NID of 12/16 [18]. The Primary Prevention
Parameters Evaluation (PREPARE) study, a prospective
nonrandomised cohort-controlled ICD trial which started in
2003, enrolled 700 primary prevention patients and strategi-
cally chose VT/VF detection and therapy parameters to reduce
shocks and other morbidities. VT/VF was detected for rates
≥182 beats per minute (bpm) that was sustained for at least 30
out of 40 beats. ATP was programmed as first therapy for
regular rhythms with rates of 182–250 bpm, and supraven-
tricular tachycardia discriminators were used for rhythms
≤200 bpm. The control group consisted of 689 primary pre-
vention patients from the Comparison of Empiric to
Physician-Tailored Programming of Implantable Cardioverter
Defibrillators (EMPIRIC) and the Multicenter InSync Im-
plantable Cardioversion Defibrillation Randomized Clinical
Evaluation (MIRACLE ICD) trials for whom VT/VF detec-
tion and therapy programming were not controlled. The PRE-
PARE study demonstrated that programming a monitor zone
without ICD intervention for slower VT episodes, longer
arrhythmia-detection duration (i.e. NID 30/40) both in the fast
VT ≥182 bpm and VF zone ≥250 bpm, and the use of
supraventricular detection discrimination algorithms were as-
sociated with reductions in both appropriate and inappropriate
shocks in the first year (9 vs. 17 %) and reductions in mor-
bidity index events (0.26 events/patient-year for PREPARE
study patients vs. 0.69 for control cohort patients) [19]. In the
recently completed PainFREE SST study, which started in
2009, the safety of extending VT/VF interval detection dura-
tion (18/24 vs. 30/40 intervals) is assessed. Primary
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prophylactic patients received a VF NID of 30/40, while
secondary prophylactic patients were randomised to a VF
NID of either 18/24 or 30/40 [20]. Results from this study
are expected soon. The MADIT-RIT (Reduce Inappropriate
Therapy), a large-scale, randomised trial which also started in
2009, assessed the impact of high-rate cut-offs and longer
delays than standard programming on inappropriate therapy
in primary prevention patients receiving an ICD (dual-
chamber) or CRT-D. A total of 1500 hundred patients were
randomly assigned to one of three programming configura-
tions: conventional (VT between 170–199 bpm with a 2.5-s
delay and VT/SVT discriminators turned on; VF ≥200 bpm
with a 1-s delay before delivery of ATP or shock), high rate
(VT monitoring between 170–199 bpm; VF ≥200 bpm with a
duration of 2.5-s) and delayed therapy (VT-1 between 170–
199 bpm, with rhythm detection on and a 60-s delay before
initiation of therapy; VT-2 ≥200 bpm, with rhythm detection
on and a 12-s delay before therapy; and VF ≥250 bpm with a
2.5-s delay before initiation of therapy). As compared with the
conventional-therapy group, the high-rate and delayed-
therapy groups had significantly fewer patients with a first
and total occurrence of appropriate or inappropriate therapy
[21]. Findings were dominated by reductions in ATP. First
occurrences of inappropriate ATP and shocks were most fre-
quent with regular SVT and atrial fibrillation. The fact that
also appropriate ATP occurred less often demonstrated that
many VTepisodes terminated spontaneously and did not need
any ICD therapy [21]. Finally, the ADVANCE III trial, a
randomised controlled clinical trial which started in 2008,
assessed whether increasing the NID is an effective strategy
to further reduce appropriate and inappropriate ICD interven-
tion in any type of ICD (single-chamber, dual-chamber, CRT-
D), among patients with both primary and secondary ICD
indications. ADVANCE III demonstrated that the use of a
long detection setting (NID 30/40) in ICDs with the capability
of delivering ATP during capacitor charge significantly re-
duced the rate of appropriate therapies (ATP and shocks) and
inappropriate shocks compared with the standard detection
setting (NID 18/24) [13]. Mortality and syncope rates did
not significantly differ between the groups. A NID of 30/40
also avoided an appropriate shock in 54 % of the sustained
episodes with cycle length between 240–320 ms. These re-
sults confirmed and reinforced, in a larger population, the
main results presented by the MADIT-RIT trial.
ICD therapy and psychological well-being
Shocks have also been shown to impact adversely on mental
well-being and physical functioning [22, 23], although the
evidence for an adverse effect of shocks on these outcomes
is not consistent, even in the major primary and secondary
prevention trials that included quality of life as a secondary
endpoint [24]. Moreover, there is increasing evidence that the
psychological status and profile of the ICD patient is an
important determinant of both the onset of VT [25–27], but
also survival [27–30].
ENHANCED-ICD study
Despite new detection algorithms approximately 2 % of pri-
mary and secondary prophylactic ICD patients receive an
inappropriate shock during the first year [17]. The number
of appropriate but unnecessary ICD therapies may be even
higher. One important tool to reduce both appropriate and
inappropriate ICD therapy is to prolong the tachycardia de-
tection duration. To provide an example, a patient with a VTof
200 bpm (cycle length =300 ms) and a NID of 30/40, may
already receive ATP after 9 s (30 * 300 ms =9000 ms).
However, ICD therapy might be unnecessary because of
spontaneous termination of an episode after 9 s, as illustrated
in Fig. 1. In this patient from the on-going ENHANCED-ICD
study, unnecessary ATP could be avoided by prolonging the
NID to 60/80.
The on-going ENHANCED-ICD study should be seen as
an extension of the PREPARE, PainFREE SST and AD-
VANCE III trials rather than a duplicate, as this study aims
to reduce the number of ICD therapies even further (by
increasing the NID to 60/80), while also including the patient
perspective by using questionnaires on patient quality of life
in the broadest sense due to inclusion of anxiety and depres-
sion and other psychological risk markers that have been
shown to influence not only time to onset of tachyarrhythmias
but also mortality in ICD patients. The ENHANCED-ICD
study is a prospective, single-arm safety monitoring study
which was designed together with Tilburg University and
implemented in the University Medical Center Utrecht
(UMCU), the Netherlands. Patients implanted with a CE-
approved and market-released ICD (single-chamber or dual-
chamber) or CRT-D device with SST, between 18–80 years of
age, and eligible for primary or secondary prophylactic ICD or
CRT-D therapy according to the current guidelines were eli-
gible to participate. Patients on the waiting list for heart
transplantation, with a history of psychiatric illness other than
affective/anxiety disorders, or unable to complete the ques-
tionnaires due to cognitive impairments, or insufficient
knowledge of the Dutch languagewere excluded. The primary
objective of the study is to investigate whether enhanced
programming (VT monitoring zone >166/min; FVT zone ≥
182/min via VF NID 60/80 with 3x ATP and if unsuccessful
followed by shock; VF ≥250/min with 1x ATP during charg-
ing and if unsuccessful followed by shock) to reduce therapy
is safe for patients with a primary or secondary ICD indica-
tion. The secondary objective is to examine the impact of
enhanced programming on (i) ATP and shocks (both appro-
priate and inappropriate) and (ii) quality of life and distress.
Based on the sample size calculation, we needed to include at
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least 60 patients in our study to be able to decide on whether
enhanced programming is safe or not. Enhanced program-
ming is considered safe if the number of arrhythmic syncopes
and other intervention-related safety events (either
hospitalisation, death or other serious adverse event due to
Enhanced programming) does not exceed the safety threshold.
To closely monitor safety, an established, sequential safety
monitoring model is used [31]. The study will be prematurely
closed if the number of intervention-related safety events
exceeds the safety threshold. Patient inclusion started on 15
Fig 1 EGM of an ENHANCED-ICD patient whose VT spontaneously terminated after >30 intervals
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April 2013 and the last patient was included on 20 December
2013. The device follow-up assessments take place at 2, 6 and
12 months post implantation (standard procedure), and every
6 months afterwards until the last included patient has com-
pleted the 12-month follow-up (end of study). In addition, all
patients were connected to remote patient monitoring. At
baseline (pre-implantation), 3, 6 and 12 months post-
implantation patients fill in a questionnaire measuring quality
of life and distress.
In conclusion, considerable efforts have been made to
reduce inappropriate and unnecessary device therapy (ATP
and shock) in ICD patients. As recently stated by Helmut
Klein (adjunct professor of Medicine, University of Rochester
Medical Center, USA), ‘there is a paradigm shift of ICD
programming to less fast and aggressive arrhythmia termina-
tion using prolonged detection, delayed intervention and no
therapy delivery for slower and stable VT events, allowing
them to terminate spontaneously’ [32]. The ENHANCED-
ICD study will examine if further reductions in inappropriate
and unnecessary ICD therapy are possible and look at the
associated impact on patient well-being, with results expected
in 2015.
Registration The ENHANCED-ICD study is registered at
ClinicalTrials.gov with study ID NCT01715116
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